TYCRUVA
DEAD

Serial Number

97086440

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Xiomara Triana

Filing Date

Oct 21, 2021

Add to watchlist:

No watchlists yet
View on USPTO

TYCRUVA Trademark

Serial Number: 97086440

TYCRUVA is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on October 21, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

October 21, 2021

Registration Date

Not Registered

Published for Opposition

February 28, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 27, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 27, 2023 ABN6
ASSIGNED TO EXAMINER
Oct 23, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 25, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 28, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 28, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 8, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 21, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 21, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 26, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 9, 2021 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 7, 2021 NWOS
NEW APPLICATION ENTERED
Oct 25, 2021 NWAP